Asset profile
Tenofovir alafenamide/emtricitabine · Descovy
Small molecule
Evidence outlook
Approved: HIV
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 49 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tenofovir Alafenamide / Emtricitabine (Descovy): this drug | Approved | Small molecule | HIV reverse transcriptase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Rilpivirine (Edurant) | Approved | Small molecule | HIV reverse transcriptase | ||
| Alimatravir | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Dapivirine (Dapivirine Vaginal Ring) | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Ulonivirine | Phase 2/3 | Small molecule | HIV reverse transcriptase | ||
| CL-197 | Phase 2 | Small molecule | HIV reverse transcriptase | ||
| Ainuovirine | Phase 1 | Small molecule | HIV reverse transcriptase | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
January 2027 (1)
August 2027 (1)
December 2027 (1)
2028 (2)
2029 (1)
September 2029 (1)
What to watch
2030 (1)
October 2030 (1)
2034 (1)
March 2034 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.